Open AccessComparison of the Roche COBAS AmpliPrep/COBAS TaqMan HIV‐1 test v1.0 with v2.0 in HIV‐1 viral load quantification
Author(s) -
Tung YiChing,
Ke LiangYin,
Lu PoLiang,
Lin KueiHsiang,
Lee SuChen,
Lin YiYing,
Chou LiChiu,
Tsai WenChan
Publication year - 2015
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1016/j.kjms.2014.12.010
Subject(s) - medicine , viral load , human immunodeficiency virus (hiv) , taqman , concordance , virology , real time polymerase chain reaction , biology , biochemistry , gene
Roche modified the COBAS AmpliPrep/COBAS TaqMan human immunodeficiency virus type 1 (HIV‐1) test version 1.0 (CAP/CTM v1.0), resulting in the COBAS AmpliPrep/COBAS TaqMan HIV‐1 test version 2.0 (CAP/CTM v2.0). The aim of this study was to evaluate the performance of the CAP/CTM v2.0 and to compare this performance with that of the CAP/CTM v1.0. The study was conducted in a small local study group in Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. A total of 86 plasma samples from HIV‐1‐seropositive patients were tested using the two assays. The correlation and concordance of results between the two assays were calculated. The CAP/CTM v2.0 generated higher values than did the CAP/CTM v1.0, and five samples (5.8%) yielded a difference of > 1 log 10 copies/mL. In addition, our data show that CAP/CTM v1.0 and CAP/CTM v2.0 yielded relatively consistent values for 23 samples with low viral loads (< 200 copies/mL). Furthermore, when viral loads were in a medium range (2–5 log 10 copies/mL), the results of the two assays were more compatible. This study shows a good correlation between CAP/CTM v1.0 and v2.0 in HIV‐1 viral load measurement. Further attention must be paid to those cases in which measured viral loads present larger differences between the two assays.